CeMM Level 8, Seminar Room
Matthew Vander Heiden
Associate Director, Koch Institute for Integrative Cancer Research at MIT, Cambridge MA, USA
"Metabolic limitations of tumor growth"
Host: Giulio Superti-Furga
Biosketch:
Dr. Vander Heiden earned a BS in Biological Chemistry, an MD, and a PhD from the University of Chicago, and completed his clinical training in internal medicine and medical oncology at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. After postdoctoral research at Harvard Medical School, Vander Heiden joined the faculty of the MIT Department of Biology and the Koch Institute in 2010. Among Vander Heiden’s awards and honors include a Burroughs Wellcome Fund Career Award for Medical Sciences, a Damon Runyon-Rachleff Innovation Award, a Stand Up To Cancer Innovative Research Grant, and being named a Howard Hughes Medical Institute Faculty Scholar.
Dr. Vander Heiden is recognized as one of the leading experts in the field of cancer metabolism. As a clinical fellow in the laboratory of Lewis Cantley, Ph.D. at Beth Israel Deaconess Medical Center, he participated in the identification of pyruvate kinase M2 regulating glucose metabolism in proliferating cells, as published in the journal Nature.
His laboratory is currently studying how mammalian cell metabolism is adapted to support function, with a particular focus on the role metabolism plays in cancer. He uses mouse models to study how changes in metabolism impact all aspects of cancer progression with a goal of finding novel ways to exploit altered metabolism to help patients.
CeMM Level 8, Seminar Room
Franziska Michor
Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology, Boston, USA
"DNA methylation profiling for non-invasive early cancer diagnosis"
Host: Giulio Superti-Furga
Biosketch:
Dr. Michor is a Professor of Computational Biology in the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University. Dr. Michor obtained her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the director of the Dana-Farber Cancer Institute Physical Sciences-Oncology Center and the Center for Cancer Evolution. She has been the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award, the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others. Dr. Michor's laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.
CeMM Level 8, Seminar Room
Nicolas Thomä
FMI Basel, Switzerland
"The CRL4 ubiquitin ligase: at the intersection of genome stability and drug discovery"
Host: Georg Winter
